ALDH2 (Aldehyde Dehydrogenase 2 Family Member)

Collectively, these findings identify ALDH2 as a key tumor suppressor in HNSC, including OSCC, and highlight the therapeutic potential of activating ALDH2, NR4A1, and TGM2. Moreover, stabilization of the ALDH2-ALDH6A1 complex may offer a viable strategy for disease prevention and treatment, even in the context of frequent ALDH2 mutations.

By integrating multi-ethnic multi-omics data, we highlight emerging biomarkers and therapeutic targets that may inform ancestry-aware screening, risk stratification, and individualized treatment strategies. Bridging these ethnic and molecular divides is essential for translating genomic discoveries into equitable precision oncology for ESCC.

Heavy smoking was associated with the development of LVLs and poor prognosis in those with double primary cancers. ALDH2 and CYP2A6 may contribute to cancer risk, underscoring the importance of abstinence from alcohol and smoking in preventive healthcare.

Drug sensitivity analysis revealed that the high-risk group was more sensitive to fluorouracil and gemcitabine (P<0.001), whereas the low-risk group showed better responses to regorafenib (P=0.007). This study establishes a novel prognostic model for COAD based on cofactor and vitamin metabolism, enabling precise survival prediction and guiding personalized therapeutic strategies. The model underscores the interplay between metabolic-immune crosstalk and chemotherapy response heterogeneity, providing a framework for developing targeted metabolic therapies combined with immune modulation.

Nine of these genes showed significant prognostic relevance. The current work identifies key biomarkers that can enhance ccRCC diagnosis and guide future therapy.

This study is the first to analyze the regulatory network of palmitoylation in HCC epithelial cells by combining single-cell and bulk transcriptomes, providing new molecular targets and methodological references for HCC prognosis evaluation and precision therapy.

Currently, the discovery and development of drugs targeting ALDH2 are receiving increasing attention, and several modulators of ALDH2 have been identified, providing promising directions for the clinical treatment of liver diseases. This review aims to summarize the biochemical and biological functions of ALDH2, as well as its role in liver diseases, and explore its potential and application prospects as a therapeutic target, which will help develop therapeutic strategies for liver diseases.

CO-IP showed ALDH2 interacted with HMGB1, RAGE, and GSDMD. ALDH2 protects the myocardium from septic injury by inhibiting caspase-11-mediated noncanonical pyroptosis, possibly via direct interactions with GSDMD, HMGB1, and RAGE.

Single-cell analysis indicated specific expression of AKR1C3 in HCC cells, while molecular docking analysis showed that, among the five potential targets, AKR1C3 demonstrated the most stable binding affinity to rutin. Our findings suggest that rutin may modulate ferroptosis in HCC, with rutin associated ferroptosis genes implicated in disease biology; moreover, the proposed risk scoring model shows promising prognostic utility in HCC.

This study established and validated a pro-gnostic model for breast cancer based on lipid metabolism-related genes. It revealed that low ALDH2 expression is closely associated with poor prognosis and immunosuppression, suggesting its potential as a prognostic biomarker and therapeutic target in breast cancer.

Baicalin exerts potent anti-tumor effects in BCa by upregulating ALDH2, thereby suppressing PD-L1-mediated M2 macrophage polarization and remodeling the tumor immune microenvironment. This mechanism provides a novel therapeutic strategy for combating BCa progression.

An overview of dyclonine pharmacology is offered. This unsung drug has not finished talked about it.